Eagle Pharmaceuticals (EGRX) Short Interest Ratio & Short Volume $2.70 -0.05 (-1.82%) As of 10:56 AM Eastern Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Eagle Pharmaceuticals Short Interest DataEagle Pharmaceuticals (EGRX) has a short interest of 42,500 shares, representing 0.46% of the float (the number of shares available for trading by the public). This marks a -21.88% decrease in short interest from the previous month. The short interest ratio (days to cover) is 6.4, indicating that it would take 6.4 days of the average trading volume of 8,865 shares to cover all short positions.Current Short Interest42,500 sharesPrevious Short Interest54,400 sharesChange Vs. Previous Month-21.88%Dollar Volume Sold Short$80.75 thousandShort Interest Ratio6.4 Days to CoverLast Record DateMay 31, 2025Outstanding Shares12,987,000 sharesShort Percent of Float0.46%Today's Trading Volume1,123 sharesAverage Trading Volume8,865 sharesToday's Volume Vs. Average13% Short Selling Eagle Pharmaceuticals? Sign up to receive the latest short interest report for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartEGRX Short Interest Over TimeEGRX Days to Cover Over TimeEGRX Percentage of Float Shorted Over Time Eagle Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/31/202542,500 shares $80.75 thousand -21.9%0.5%6.4 $1.90 5/15/202554,400 shares $105.54 thousand -14.7%N/A24.7 $1.94 4/30/202563,800 shares $125.05 thousand -43.4%N/A2.3 $1.96 4/15/2025112,800 shares $203.04 thousand -0.1%N/A3.7 $1.80 3/14/2025112,500 shares $146.25 thousand No ChangeN/A13.4 $1.30 2/28/2025112,500 shares $135 thousand -8.8%N/A5.4 $1.20 2/14/2025123,400 shares $144.38 thousand -63.5%N/A8.2 $1.17 1/31/2025337,700 shares $270.16 thousand -6.5%N/A13.8 $0.80 1/15/2025361,000 shares $223.82 thousand +0.3%N/A34.7 $0.62 9/30/2024371,600 shares $1.39 million +6.0%2.9%1.7 $3.73 Get the Latest News and Ratings for EGRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 9/15/2024350,500 shares $1.51 million -17.3%3.1%2.4 $4.31 8/31/2024423,800 shares $2.18 million -12.5%3.7%2.9 $5.14 8/15/2024484,200 shares $1.93 million +14.1%4.2%3.1 $3.98 7/31/2024424,400 shares $2.05 million -44.9%3.7%2.5 $4.82 7/15/2024770,600 shares $4.60 million -16.8%6.7%4.5 $5.97 6/30/2024925,900 shares $5.19 million -6.9%8.1%5.2 $5.60 6/15/2024994,400 shares $3.83 million -7.9%8.7%6.7 $3.85 5/31/20241,080,000 shares $3.75 million -5.3%9.5%7.1 $3.47 5/15/20241,140,000 shares $5.26 million -5.0%10.0%7.8 $4.61 4/30/20241,200,000 shares $4.91 million +1.7%10.5%7.7 $4.09 4/15/20241,180,000 shares $6.14 million -2.5%10.3%5.9 $5.20 3/31/20241,210,000 shares $6.34 million +4.3%10.6%5.3 $5.24 3/15/20241,160,000 shares $7.02 million +4.5%10.2%5 $6.05 2/29/20241,110,000 shares $6.50 million +4.7%9.7%4.3 $5.86 2/15/20241,060,000 shares $6.20 million +33.2%9.3%3.6 $5.85 1/31/2024796,100 shares $4.67 million +10.1%7.0%2.8 $5.86 1/15/2024723,100 shares $3.28 million +3.7%6.4%2.9 $4.53 12/31/2023697,400 shares $3.65 million +3.9%6.2%3.4 $5.23 12/15/2023671,300 shares $3.11 million +13.7%5.9%3.6 $4.63 11/30/2023590,400 shares $3.45 million -0.7%5.2%3.9 $5.85 11/15/2023594,600 shares $5.25 million -3.7%5.2%5.2 $8.83 10/31/2023617,600 shares $8.48 million +2.4%5.5%5.8 $13.73 10/15/2023602,900 shares $8.10 million +12.5%5.3%4.9 $13.43 9/30/2023536,000 shares $8.45 million -23.9%4.7%4.1 $15.77 9/15/2023704,600 shares $11.42 million +9.9%6.2%5.2 $16.21 8/31/2023640,900 shares $10.86 million -6.1%5.7%3.3 $16.95 8/15/2023682,400 shares $11.63 million +4.5%6.0%3.4 $17.04 7/31/2023653,200 shares $13.56 million -4.0%5.7%3.2 $20.76 7/15/2023680,200 shares $12.50 million +14.6%6.0%3.6 $18.37 6/30/2023593,600 shares $11.54 million -26.9%5.2%3.2 $19.44A grave, grave error. (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. 6/15/2023812,500 shares $15.41 million +18.6%7.1%4.2 $18.96 5/31/2023685,200 shares $14.22 million -1.3%6.0%4.1 $20.75 5/15/2023694,400 shares $14.60 million -3.0%6.1%4.3 $21.03 4/30/2023715,700 shares $20.10 million -5.1%6.3%4.7 $28.08 4/15/2023754,400 shares $22.41 million -19.7%6.7%4.8 $29.71 3/31/2023939,300 shares $26.65 million -7.9%8.3%5.5 $28.37 3/15/20231,020,000 shares $26.27 million +16.4%9.0%6.3 $25.75 2/28/2023876,100 shares $24.53 million +1.0%7.8%6.1 $28.00 2/15/2023867,400 shares $26.73 million -0.8%7.7%6.3 $30.82 1/31/2023874,400 shares $29.68 million -9.7%7.7%5.8 $33.94 1/15/2023968,700 shares $31.43 million -2.4%8.6%6.2 $32.45 12/30/2022992,100 shares $29.00 million +63.8%8.8%6.4 $29.23 12/15/2022605,700 shares $17.90 million -27.0%5.4%3.6 $29.55 11/30/2022830,100 shares $30.15 million -9.4%7.3%4.9 $36.32 11/15/2022915,900 shares $33.89 million +0.1%8.1%5.3 $37.00 10/31/2022915,200 shares $28.80 million -6.5%8.1%4.9 $31.47 10/15/2022978,700 shares $27.01 million +8.4%8.5%5.6 $27.60 9/30/2022903,200 shares $23.86 million +28.8%7.8%5.4 $26.42 9/15/2022701,400 shares $21.13 million -17.2%6.1%4.3 $30.12 8/31/2022846,900 shares $27.75 million +3.2%7.4%5.7 $32.77 8/15/2022820,900 shares $29.49 million -18.7%7.2%5.6 $35.92 7/31/20221,010,000 shares $40.10 million +1.0%9.2%7.4 $39.70 7/15/20221,000,000 shares $44.83 million -2.9%9.1%7.5 $44.83 6/30/20221,030,000 shares $45.76 million -7.2%9.4%7.6 $44.43 6/15/20221,110,000 shares $48.33 million +17.4%10.2%8 $43.54 5/31/2022945,600 shares $44.16 million +4.3%8.6%6.8 $46.70 5/15/2022906,800 shares $39.90 million +8.2%8.3%6.8 $44.00 4/30/2022838,200 shares $36.99 million +20.1%7.7%6.4 $44.13 4/15/2022697,800 shares $35.20 million -3.1%6.4%5.5 $50.44 3/31/2022719,800 shares $35.62 million +4.4%N/A5.5 $49.49 3/15/2022689,700 shares $34.69 million +14.0%6.3%5.9 $50.30 2/28/2022604,900 shares $28.67 million -10.2%5.4%4.8 $47.39 2/15/2022673,200 shares $32.15 million +1.1%6.0%5.6 $47.76 1/31/2022665,700 shares $30.58 million +12.4%5.9%5.9 $45.94 1/15/2022592,400 shares $27.97 million +2.3%N/A5.6 $47.21 12/31/2021579,300 shares $29.50 million -1.0%5.2%6 $50.92 12/15/2021585,100 shares $30.60 million -5.5%5.2%5.8 $52.30 11/30/2021618,900 shares $29.51 million -3.3%5.5%7.1 $47.68 11/15/2021639,900 shares $32.62 million -7.1%5.7%6.9 $50.98 10/29/2021689,000 shares $36.08 million -1.7%6.0%7 $52.37 10/15/2021701,000 shares $38.12 million -11.3%6.1%7 $54.38 9/30/2021790,700 shares $44.11 million -4.8%6.9%7.6 $55.78 9/15/2021830,500 shares $43.92 million -3.3%7.3%7.2 $52.88 8/31/2021859,200 shares $45.86 million -6.7%7.5%7.4 $53.37 8/13/2021920,800 shares $44.91 million -5.0%8.1%7.7 $48.77 7/30/2021969,000 shares $45.06 million +4.6%8.5%8.5 $46.50 7/15/2021926,100 shares $43.55 million -3.1%8.1%8.1 $47.02 6/30/2021955,800 shares $40.91 million -7.2%8.4%8.1 $42.80 6/15/20211,030,000 shares $42.73 million -2.8%9.0%9.3 $41.49 5/28/20211,060,000 shares $42.00 million -1.9%9.3%10.1 $39.62A grave, grave error. (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. 5/14/20211,080,000 shares $43.92 million +2.9%9.4%9.8 $40.67 4/30/20211,050,000 shares $42.98 million -7.9%9.2%9.1 $40.93 4/15/20211,140,000 shares $49.44 million -16.8%N/A0 $43.37 3/31/20211,370,000 shares $56.25 million -2.1%12.2%11.2 $41.06 3/15/20211,400,000 shares $62.97 million No Change12.4%11 $44.98 2/26/20211,400,000 shares $64.09 million +7.7%12.4%10.8 $45.78 2/12/20211,300,000 shares $62.41 million -7.1%11.6%10.7 $48.01 1/29/20211,400,000 shares $65.63 million -2.1%12.4%11.7 $46.88 1/15/20211,430,000 shares $72.54 million -4.0%12.7%11.4 $50.73 12/31/20201,490,000 shares $69.29 million No Change13.2%11.5 $46.50 12/15/20201,490,000 shares $68.81 million -0.7%13.2%10.6 $46.18 11/30/20201,500,000 shares $70.97 million -3.9%13.3%10.2 $47.31 11/15/20201,560,000 shares $76.30 million -4.9%13.8%9.6 $48.91 10/30/20201,640,000 shares $75.74 million -12.3%14.5%9.8 $46.18 10/15/20201,870,000 shares $85.03 million -18.0%15.9%10.6 $45.47 9/30/20202,280,000 shares $96.85 million +27.4%19.4%13 $42.48 9/15/20201,790,000 shares $69.24 million -10.5%15.1%10 $38.68 8/31/20202,000,000 shares $79.36 million +1.5%16.9%11.3 $39.68 8/14/20201,970,000 shares $84.65 million -5.3%16.4%11.6 $42.97 7/31/20202,080,000 shares $96.49 million +0.5%15.9%11.9 $46.39 7/15/20202,070,000 shares $100.46 million +3.5%15.8%12.8 $48.53 6/30/20202,000,000 shares $95.96 million +8.7%15.3%12 $47.98 EGRX Short Interest - Frequently Asked Questions What is Eagle Pharmaceuticals' current short interest? Short interest is the volume of Eagle Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of May 31st, investors have sold 42,500 shares of EGRX short. 0.46% of Eagle Pharmaceuticals' shares are currently sold short. Learn More on Eagle Pharmaceuticals' current short interest. What is a good short interest ratio for Eagle Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EGRX shares currently have a short interest ratio of 6.0. Learn More on Eagle Pharmaceuticals's short interest ratio. What is a good short interest percentage for Eagle Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.46% of Eagle Pharmaceuticals' floating shares are currently sold short. Is Eagle Pharmaceuticals' short interest increasing or decreasing? Eagle Pharmaceuticals saw a decrease in short interest in May. As of May 31st, there was short interest totaling 42,500 shares, a decrease of 21.9% from the previous total of 54,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Eagle Pharmaceuticals' short interest compare to its competitors? 0.46% of Eagle Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Eagle Pharmaceuticals: Genelux Co. (7.05%), BeyondSpring Inc. (6.28%), Anixa Biosciences, Inc. (1.12%), Cardiol Therapeutics Inc. (2.53%), C4 Therapeutics, Inc. (9.56%), Contineum Therapeutics, Inc. (4.45%), Protalix BioTherapeutics, Inc. (1.39%), Theratechnologies Inc. (1.28%), Atossa Therapeutics, Inc. (6.56%), Zentalis Pharmaceuticals, Inc. (8.56%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($64.96 billion), Invesco QQQ ($27.88 billion), iShares Russell 2000 ETF ($19.94 billion), iShares 20+ Year Treasury Bond ETF ($9.69 billion), MicroStrategy Incorporated ($8.58 billion), SPDR S&P Biotech ETF ($5.72 billion), Invesco S&P 500 Equal Weight ETF ($5.45 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.70 billion), Charter Communications, Inc. ($4.54 billion), and Industrial Select Sector SPDR Fund ($4.49 billion). View all of the most shorted stocks. What does it mean to sell short Eagle Pharmaceuticals stock? Short selling EGRX is an investing strategy that aims to generate trading profit from Eagle Pharmaceuticals as its price is falling. EGRX shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Eagle Pharmaceuticals? A short squeeze for Eagle Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of EGRX, which in turn drives the price of the stock up even further. How often is Eagle Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EGRX, twice per month. The most recent reporting period available is May, 31 2025. More Short Interest Resources from MarketBeat Related Companies GNLX Short Squeeze BYSI Short Squeeze ANIX Short Squeeze CRDL Short Squeeze CCCC Short Squeeze CTNM Short Squeeze PLX Short Squeeze THTX Short Squeeze ATOS Short Squeeze ZNTL Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:EGRX) was last updated on 6/25/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
